Cytokinetics Stock Probability Of Bankruptcy

CYTK Stock

USD 46.36 1.42 2.97%

Cytokinetics' chance of distress is over 50% at the moment. It has a moderate odds of going through some financial hardship in the next 2 years. Odds of financial distress prediction helps decision makers evaluate Cytokinetics' chance of financial distress in relation to its going-concern outlook and evaluation. All items used in analyzing the odds of distress are taken from the Cytokinetics balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Cytokinetics Piotroski F Score and Cytokinetics Altman Z Score analysis.

For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.

Market Cap is expected to rise to about 7.6 B this year. Enterprise Value is expected to rise to about 334.5 M this year

Cytokinetics Company odds of financial distress Analysis

Cytokinetics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Cytokinetics Probability Of Bankruptcy

Over 57%

Most of Cytokinetics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytokinetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Cytokinetics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Cytokinetics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Cytokinetics financial health.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.38)

Revenue Per Share

0.03

Quarterly Revenue Growth

0.225

Return On Assets

(0.30)

Return On Equity

(5.72)

The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Current Deferred Revenue	Accounts Payable	Long Term Debt	Net Receivables	Short Term Investments	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.49	0.87	-0.91	0.94	0.46	0.98	0.62	0.17	0.97	0.99	0.88	-0.13	0.93	-0.35	0.91	0.89	0.71	0.05	0.88	0.86	0.92	0.95
Total Stockholder Equity	-0.49		-0.82	0.72	-0.75	0.23	-0.55	-0.89	0.4	-0.56	-0.52	-0.73	0.04	-0.66	0.89	-0.39	-0.49	0.09	-0.23	-0.52	-0.18	-0.43	-0.62
Net Debt	0.87	-0.82		-0.92	0.97	0.12	0.91	0.79	-0.1	0.9	0.88	0.9	-0.13	0.93	-0.73	0.75	0.78	0.38	0.03	0.77	0.7	0.84	0.92
Retained Earnings	-0.91	0.72	-0.92		-0.96	-0.34	-0.92	-0.84	-0.02	-0.91	-0.92	-0.93	0.06	-0.91	0.55	-0.84	-0.87	-0.51	-0.17	-0.87	-0.63	-0.78	-0.93
Total Liab	0.94	-0.75	0.97	-0.96		0.26	0.95	0.81	-0.03	0.94	0.94	0.94	-0.11	0.96	-0.6	0.83	0.86	0.5	0.13	0.85	0.72	0.85	0.95
Current Deferred Revenue	0.46	0.23	0.12	-0.34	0.26		0.4	0.06	0.65	0.33	0.42	0.32	0.09	0.33	0.39	0.53	0.43	0.69	-0.08	0.36	0.4	0.32	0.36
Accounts Payable	0.98	-0.55	0.91	-0.92	0.95	0.4		0.66	0.13	0.94	0.96	0.92	-0.16	0.96	-0.42	0.88	0.87	0.7	0.03	0.85	0.85	0.89	0.96
Long Term Debt	0.62	-0.89	0.79	-0.84	0.81	0.06	0.66		-0.15	0.61	0.63	0.88	-0.08	0.78	-0.61	0.52	0.63	0.19	0.32	0.58	0.24	0.46	0.71
Net Receivables	0.17	0.4	-0.1	-0.02	-0.03	0.65	0.13	-0.15		0.01	0.09	0.09	-0.02	0.13	0.56	0.21	0.16	0.57	-0.24	0.01	0.23	0.07	0.1
Short Term Investments	0.97	-0.56	0.9	-0.91	0.94	0.33	0.94	0.61	0.01		0.99	0.82	-0.08	0.88	-0.5	0.87	0.87	0.55	0.01	0.89	0.84	0.93	0.93
Total Current Assets	0.99	-0.52	0.88	-0.92	0.94	0.42	0.96	0.63	0.09	0.99		0.85	-0.1	0.9	-0.41	0.9	0.88	0.62	0.09	0.89	0.83	0.92	0.93
Short Term Debt	0.88	-0.73	0.9	-0.93	0.94	0.32	0.92	0.88	0.09	0.82	0.85		-0.16	0.98	-0.47	0.77	0.79	0.57	0.19	0.74	0.63	0.74	0.92
Common Stock	-0.13	0.04	-0.13	0.06	-0.11	0.09	-0.16	-0.08	-0.02	-0.08	-0.1	-0.16		-0.17	-0.05	-0.06	-0.25	-0.18	-0.1	0.09	-0.31	-0.26	-0.18
Property Plant Equipment	0.93	-0.66	0.93	-0.91	0.96	0.33	0.96	0.78	0.13	0.88	0.9	0.98	-0.17		-0.45	0.82	0.8	0.62	0.08	0.77	0.77	0.85	0.96
Net Tangible Assets	-0.35	0.89	-0.73	0.55	-0.6	0.39	-0.42	-0.61	0.56	-0.5	-0.41	-0.47	-0.05	-0.45		-0.26	-0.34	0.29	-0.08	-0.44	-0.16	-0.38	-0.46
Capital Surpluse	0.91	-0.39	0.75	-0.84	0.83	0.53	0.88	0.52	0.21	0.87	0.9	0.77	-0.06	0.82	-0.26		0.83	0.72	0.05	0.94	0.76	0.86	0.93
Deferred Long Term Liab	0.89	-0.49	0.78	-0.87	0.86	0.43	0.87	0.63	0.16	0.87	0.88	0.79	-0.25	0.8	-0.34	0.83		0.69	-0.06	0.85	0.68	0.76	0.85
Long Term Investments	0.71	0.09	0.38	-0.51	0.5	0.69	0.7	0.19	0.57	0.55	0.62	0.57	-0.18	0.62	0.29	0.72	0.69		-0.14	0.57	0.69	0.56	0.62
Short Long Term Debt	0.05	-0.23	0.03	-0.17	0.13	-0.08	0.03	0.32	-0.24	0.01	0.09	0.19	-0.1	0.08	-0.08	0.05	-0.06	-0.14		0.08	-0.17	-0.07	0.04
Long Term Debt Total	0.88	-0.52	0.77	-0.87	0.85	0.36	0.85	0.58	0.01	0.89	0.89	0.74	0.09	0.77	-0.44	0.94	0.85	0.57	0.08		0.62	0.77	0.87
Net Invested Capital	0.86	-0.18	0.7	-0.63	0.72	0.4	0.85	0.24	0.23	0.84	0.83	0.63	-0.31	0.77	-0.16	0.76	0.68	0.69	-0.17	0.62		0.94	0.8
Net Working Capital	0.92	-0.43	0.84	-0.78	0.85	0.32	0.89	0.46	0.07	0.93	0.92	0.74	-0.26	0.85	-0.38	0.86	0.76	0.56	-0.07	0.77	0.94		0.92
Capital Stock	0.95	-0.62	0.92	-0.93	0.95	0.36	0.96	0.71	0.1	0.93	0.93	0.92	-0.18	0.96	-0.46	0.93	0.85	0.62	0.04	0.87	0.8	0.92

	2019	2020	2021	2022	2023	2024 (projected)
Return On Assets	(0.51)	(0.31)	(0.29)	(0.4)	(0.64)	(0.67)
Asset Turnover	0.0927	0.1	0.0837	0.0932	0.009135	0.008678
Gross Profit Margin	(2.21)	(0.74)	(1.27)	(1.55)	(42.84)	(40.7)
Net Debt	99.6M	56.0M	157.3M	683.8M	642.7M	674.9M
Total Current Liabilities	26.0M	31.2M	71.9M	84.6M	102.7M	107.8M
Non Current Liabilities Total	274.7M	389.2M	525.6M	1.0B	1.1B	1.2B
Total Assets	289.8M	533.8M	841.3M	1.0B	824.3M	865.5M
Total Current Assets	233.8M	474.2M	535.7M	795.2M	628.1M	659.5M
Total Cash From Operating Activities	(90.9M)	8.9M	(142.5M)	(299.5M)	(414.3M)	(393.6M)

	Return On Equity	-5.72
	Return On Asset	-0.3
	Operating Margin	(304.11) %
	Current Valuation	5.42 B
	Shares Outstanding	118.01 M
	Shares Owned By Insiders	0.53 %
	Shares Owned By Institutions	99.47 %
	Number Of Shares Shorted	14.03 M
	Price To Earning	(37.76) X
	Price To Book	60.31 X
	Price To Sales	1,752 X
	Revenue	7.53 M
	Gross Profit	(146.22 M)
	EBITDA	(456.68 M)
	Net Income	(526.24 M)
	Cash And Equivalents	586.03 M
	Cash Per Share	6.22 X
	Total Debt	755.77 M
	Debt To Equity	2.93 %
	Current Ratio	9.01 X
	Book Value Per Share	(0.12) X
	Cash Flow From Operations	(414.33 M)
	Short Ratio	10.52 X
	Earnings Per Share	(5.38) X
	Price To Earnings To Growth	(0.42) X
	Target Price	80.56
	Number Of Employees	423
	Beta	0.78
	Market Capitalization	5.64 B
	Total Asset	824.32 M
	Retained Earnings	(2.11 B)
	Working Capital	525.37 M
	Current Asset	113.11 M
	Current Liabilities	31.65 M
	Net Asset	824.32 M

Cytokinetics Stock Probability Of Bankruptcy

Cytokinetics Company odds of financial distress Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current Cytokinetics Probability Of Bankruptcy

Cytokinetics Probability Of Bankruptcy Driver Correlations

Cytokinetics Probability Of Bankruptcy Peer Comparison

Cytokinetics Main Bankruptcy Drivers

Cytokinetics ESG Sustainability

Cytokinetics Fundamentals

About Cytokinetics Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY